Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
BETAMETHASONE, Placebo of fludrocortisone, HYDROCORTISONE HEMISUCCINATE, Placebo of hydrocortisone, FLUDROCORTISONE
Pari Pharma GmbH
Patients admitted to the ICU proven or suspected infection as the main diagnosis.
1 trial -
Barley beta-glucan(3.0g)
Hospital Authority, Hong Kong
Overweight; Hyperlipidemia
1 trial -
Betahistine dihydrochloride, BETASERC 24 mg, comprimé
Lacuna Pharma Pty Ltd
Menière's disease
1 trial -
Betamethasone Microsphere (DE-102) Low Dose
Santen Oy
Diabetic Macular Edema
1 trial -
CEFTAZIDIME, PIPERACILLIN, CEFTAZIDIME AND BETA-LACTAMASE INHIBITOR , CEFTOLOZANE, CEFTAZIDIME, CEFEPIME , CEFEPIME, MEROPENEM , TAZOBACTAM, TAZOBACTAM, MEROPENEM, AMIKACIN , AMIKACIN, PIPERACILLIN AND BETA-LACTAMASE INHIBITOR , CEFTOLOZANE AND BETA-LACTAMASE INHIBITOR , AVIBACTAM, CEFTAZIDIME
Pari Pharma GmbH
antibiotic therapy in Sepsis
1 trial -
CTX001
Vertex Pharmaceuticals (Australia) Pty.
Beta-Thalassemia
1 trial -
CTX001
S.A.
Beta-Thalassemia
3 trials -
Clinical study to compare the therapeutic effects of two ointments with active substances betamethasone dipropionate and salicylic acid and of one ointment without active substances for patients with chronic stable plaque poriasis
Alphapharm Pty Ltd
Chronic stable plaque psoriasis
1 trial -
DAPAGLIFLOZIN, PLACEBO
Disc Medicine
Hypomagnesemia due to HNF1beta mutation
1 trial -
Donanemab, Florbetapir F18, Flortaucipir F18, Flortaucipir, FLORBETAPIR, SODIUM CHLORIDE PH. EUR.
Eli Lilly Co.
Alzheimer Disease Dementia Brain Diseases Central Nervous System Diseases Nervous System Diseases Tauopathies Neurodegenerative Diseases Neurocognitive Disorders Mental Disorders
1 trial -
FLORTAUCIPIR (18F), FLORTAUCIPIR (18F), FLORBETAPIR (18F), FLORBETAPIR (18F)
The George Institute
Semantic Variant Primary Progressive Aphasia, Alcohol Use Disorder, Organic amnesia syndrome, Narcolepsy, Alzheimer, Lewy Body Dementia
1 trial -
FLUCONAZOLE , SULFAMETHOXAZOLE AND TRIMETHOPRIM , AMOXICILLIN , METRONIDAZOLE , CIPROFLOXACIN , AMOXICILLIN AND BETA-LACTAMASE INHIBITOR , CLINDAMYCIN , DOXYCYCLINE , LINEZOLID , SODIUM CHLORIDE SOLUTION 0.9%
The George Institute
Patients with hip or knee infections
1 trial -
GENTAMICIN , CEFAZOLIN , VANCOMYCIN , TEDIZOLID , PRISTINAMYCIN , SULFAMETHOXAZOLE AND TRIMETHOPRIM , CEFOTAXIME, CEFTAROLINE FOSAMIL , AMOXICILLIN , OFLOXACIN , CLINDAMYCIN , TIGECYCLINE , LINEZOLID , AMIKACIN , LYMECYCLINE , CEFTRIAXONE , TEICOPLANIN , DOXYCYCLINE , PIPERACILLIN AND BETA-LACTAMASE INHIBITOR , Xydalba 500 mg powder for concentrate for solution for infusion, LEVOFLOXACIN , DELAFLOXACIN , CIPROFLOXACIN , CLOXACILLIN , OXACILLIN , DAPTOMYCIN , AMOXICILLIN AND BETA-LACTAMASE INHIBITOR , RIFAMP
Pari Pharma GmbH
Catheter related bloodstream infections due to Staphylococcus aureus
1 trial -
JNJ-75276617, Venclyxto 100 mg film-coated tablets, matching the 100 mg (G030), matching the 30 mg (G031), Venclyxto 100 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, JNJ-75276617, JNJ-75276617, matching the 50 mg (G029), JNJ-75276617, Azacitidine betapharm 25 mg/mL powder for suspension for injection
Janssen-Cilag International N.V.
Acute Myeloid Luekemia
1 trial -
METHOTREXATE, Dazukibart, AZATHIOPRINE, HYDROCORTISONE, DEXAMETHASONE, METHYLPREDNISOLONE, CHLOROQUINE PHOSPHATE, MYCOPHENOLATE MOFETIL, BETAMETHASONE, METHYLPREDNISOLONE, PREDNISOLONE, TRIAMCINOLONE ACETONIDE, LEFLUNOMIDE, HYDROXYCHLOROQUINE, DEFLAZACORT, BETAMETHASONE, PREDNISONE, BUDESONIDE, METHOTREXATE
Pfizer Australia Pty Ltd
Idiopathic Inflammatory Myopathy (including dermatomyositis or polymyositis)
1 trial -
MITAPIVAT, Placebo for Mitapivat
Lacuna Pharma Pty Ltd
Transfusion-Dependent Alpha- or Beta-Thalassemia
1 trial -
PIPERACILLIN AND BETA-LACTAMASE INHIBITOR , NEGABAN 2 g, poudre pour solution injectable/pour perfusion, MEROPENEM ARROW 1 g, poudre pour solution injectable / pour perfusion
Pari Pharma GmbH
patients hospitalized in ICU with ESBL-producing Enterobacteriaceae severe infection
1 trial -
PREDNISOLONE, CORTISONE ACETATE, FLUDROCORTISONE, Gohibic, TRIAMCINOLONE, PREDNISONE, DEXAMETHASONE, HYDROCORTISONE, METHYLPREDNISOLONE, IFX-1 placebo is formulated as PBS (150 mM sodium chloride, 10 mM sodium phosphate, pH 7.0) with 0.05% polysorbate 80. IFX-1 placebo is diluted in sterile 0.9% sodium chloride to the required concentration and volume. This diluent is a commercial product not accompanying IFX-1 placebo., BETAMETHASONE
InflaRx GmbH
ulcerative pyoderma gangrenosum
1 trial -
PRISTINAMYCIN , AMOXICILLIN , CEFTRIAXONE , LEVOFLOXACIN , AMOXICILLIN AND BETA-LACTAMASE INHIBITOR , CEFOTAXIME PANPHARMA 1 g, poudre pour solution injectable (IM-IV), -
Pari Pharma GmbH
Community-acquired pneumonia
1 trial -
Placebo de formule développée spécifiquement pour la recherche par la PUI (cf IMPD-Q), CLOBETASOL PROPIONATE
Pari Pharma GmbH
Adult patients with symptomatic and inflammatory Hand osteoarthritis HOA.
1 trial -
Placebo for Mitapivat, MITAPIVAT
Lacuna Pharma Pty Ltd
Non–Transfusion-Dependent Alpha- or Beta-Thalassemia
1 trial -
Pred Forte 10 mg/ml colirio en suspensión, Clobetasol propionate ophthalmic nanoemulsion, 0.05%
Laboratorios Tillomed Spain S.L.U
Inflammation and pain associated with ocular surgery
1 trial -
RIFAXIMIN , VANCOMYCIN , Entyvio 300 mg powder for concentrate for solution for infusion, AMOXICILLIN AND BETA-LACTAMASE INHIBITOR , CIPROFLOXACIN , METRONIDAZOLE
Takeda
Active Chronic Pouchitis
1 trial -
Reblozyl 75 mg powder for solution for injection, Reblozyl 25 mg powder for solution for injection
Celgene Europe Limited
myelodysplastic syndrome (MDS); beta (β)-thalassemia (THAL); myelofibrosis (MF)
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources